Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Viking Therapeutics (VKTX) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $7.8 million.

  • Viking Therapeutics' Non Operating Income fell 3307.51% to $7.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.4 million, marking a year-over-year increase of 755.67%. This contributed to the annual value of $41.0 million for FY2024, which is 17429.68% up from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Non Operating Income is $7.8 million, which was down 3307.51% from $9.0 million recorded in Q2 2025.
  • Viking Therapeutics' Non Operating Income's 5-year high stood at $11.8 million during Q2 2024, with a 5-year trough of $142000.0 in Q1 2022.
  • In the last 5 years, Viking Therapeutics' Non Operating Income had a median value of $4.5 million in 2023 and averaged $4.5 million.
  • As far as peak fluctuations go, Viking Therapeutics' Non Operating Income plummeted by 8452.61% in 2021, and later skyrocketed by 216884.42% in 2023.
  • Viking Therapeutics' Non Operating Income (Quarter) stood at $154000.0 in 2021, then soared by 370.13% to $724000.0 in 2022, then soared by 546.41% to $4.7 million in 2023, then soared by 131.22% to $10.8 million in 2024, then dropped by 28.16% to $7.8 million in 2025.
  • Its last three reported values are $7.8 million in Q3 2025, $9.0 million for Q2 2025, and $9.8 million during Q1 2025.